Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
諾華 Radioligand Therapy Lutathera FDA 批准了第一款專門用於胃腸胰腺神經內分泌腫瘤兒科患者的藥物
-
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients
-
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease
- Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers
-
批准基於NETTER-P試驗，在該試驗中，Lutathera在兒科（12-17歲）和成年患者之間表現出穩定的安全性和相似的藥物暴露量
-
胃腸胰腺神經內分泌腫瘤（GEP-NETs）是一種罕見的癌症，通常無法切除，通常在疾病的晚期被診斷出來
- 諾華是放射配體療法（RLT）領域的領導者，正在研究用於治療各種癌症的RLT產品組合，包括GEP-Net、肺癌、前列腺癌、乳腺癌、結腸癌、腦癌和胰腺癌
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。